Answers are grounded in this paper and cite their sources.
Cancer cell plasticity—the capacity of tumor cells to alter phenotypic and functional states under microenvironmental and therapeutic pressure—contributes to invasion, metastasis, and therapy resistance, but is poorly captured by endpoint assays. This review asks which manifestations of plasticity current imaging and spatially resolved technologies can detect, and which conclusions their signals support. We critically reviewed studies using fluorescent and bioluminescent reporters, intravital microscopy, tissue clearing and light-sheet microscopy, spatial transcriptomics, multiplexed imaging, MRI, PET, liquid biopsy, and computational image analysis, prioritizing work that combined imaging with lineage tracing, functional perturbation, or clinical outcomes, and compared approaches using a state–space–time–causality–translation framework. Each approach resolves a defined cellular state, spatial scale, and temporal window. Reporters and intravital microscopy capture cellular dynamics but remain largely preclinical; spatial profiling provides molecularly rich snapshots without temporal history; MRI, PET, and liquid biopsy are clinically accessible but indirect. Lineage-tracing studies show that observed phenotypes must be distinguished from demonstrated state transitions, and few imaging-derived signals have been validated as biomarkers of plasticity. Integrating longitudinal imaging with spatial profiling, lineage tracing, and targeted perturbation is required to separate correlates of metastasis and therapy resistance from causal drivers and to develop clinically validated biomarkers.
No takes yet. Share an insight, caveat, or question.
Leśniak et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: